3-(2,4-diethylcarbamoyloxy-phenyl)-4-(naphthalen-1-yl)-5-(ethylcarbamoylsulfanyl)-[1,2,4]triazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(2,4-diethylcarbamoyloxy-phenyl)-4-(naphthalen-1-yl)-5-(ethylcarbamoylsulfanyl)-[1,2,4]triazole
• 英文别名: 3-(2,4-diethylcarbamoyloxyphenyl)-4-(naphthlen-1-yl)-5-(ethylcarbamoylsulfanyl)-[1,2,4]triazole；3-(2,4-diethylcarbamoyloxy-phenyl)-4-(naphthalen-1-yl)-5-(ethylcarbamoylsulfanyl)-triazole；3-(2,4-diethylcarbamoyloxy-phenyl)-4-(naphthalen-1-yl)-5-(ethylcarbamoylsulfanyl)triazole；[3-(ethylcarbamoyloxy)-4-[5-(ethylcarbamoylsulfanyl)-4-naphthalen-1-yl-1,2,4-triazol-3-yl]phenyl] N-ethylcarbamate
• 化学式: C₂₇H₂₈N₆O₅S
• 分子量: 548.623
• InChiKey: KPBYEYPLHGALIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  39
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  162
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  3-(2,4-dihydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-[1,2,4]triazole 、 异氰酸乙酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以58%的产率得到3-(2,4-diethylcarbamoyloxy-phenyl)-4-(naphthalen-1-yl)-5-(ethylcarbamoylsulfanyl)-[1,2,4]triazole
  参考文献：
  名称：

  Method for treating proliferative disorders associated with mutations in c-Met

  摘要：

  本发明涉及在需要的人体中抑制Hsp90活性的方法，以及治疗需要的人体中与c-Met相关的癌症的方法。

  公开号：

  US09108933B2

文献信息

• Triazole compounds that modulate Hsp90 activity
  申请人：Sun Lijun

  公开号：US20080176840A1

  公开（公告）日：2008-07-24

  The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

  本发明涉及替代三唑化合物和包含替代三唑化合物的组合物。该发明还涉及在需要的受试者中抑制Hsp90活性的方法，以及预防或治疗过度增殖性疾病，如癌症，的方法，包括向受试者施用本发明的替代三唑化合物或包含这种化合物的组合物。
• Method for treating proliferative disorders associated with protooncogene products
  申请人：Du Zhenjian

  公开号：US20080004266A1

  公开（公告）日：2008-01-03

  The present invention relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating Bcr-Abl, FLT-3, EGFR, c-Kit, B-raf, and NPM-ALK associated cancers, in a subject in need thereof.

  本发明涉及抑制Hsp90在需要的受试者中的活性的方法，以及治疗Bcr-Abl、FLT-3、EGFR、c-Kit、B-raf和NPM-ALK相关癌症的方法，适用于需要的受试者。
• Synthesis of triazole compounds that modulate HSP90 activity
  申请人：Chimmanamada Dinesh U.

  公开号：US20080125587A1

  公开（公告）日：2008-05-29

  The present invention provides novel methods of preparing triazole compounds which inhibit the activity of Hsp90. One embodiment of the invention is directed to methods for preparing a triazole compound represented by the following Structural Formula: or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof, comprising the steps of: a) reacting an amide represented by the following Structural Formula: with a thionation reagent to form a thioamide; b) reacting the thioamide of step a) with hydrazine to form a hydrazonamide; c) reacting the hydrazonamide of step b) with a carbonylation or a thiocarbonylation reagent. In one embodiment, the present invention is a method of synthesis of a compound of formula (IA) or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof, comprising reacting a compound of formula (IIA) with an oxidizing agent, thereby producing a compound of formula (IA). The present invention is also directed to a method of preparing a compound or a tautomer thereof represented by the following Structural Formula: or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof. The method comprises the step of reacting a first starting compound represented by the following Structural Formula: in the presence of a mercuric salt, with a second starting compound represented by the following Structural Formula:

  本发明提供了制备三唑化合物的新方法，该化合物抑制Hsp90的活性。发明的一种实施例涉及制备由以下结构式表示的三唑化合物的方法：或其互变异构体、药学上可接受的盐、溶剂合物、包合物或前药，包括以下步骤：a)将由以下结构式表示的酰胺与硫化试剂反应以形成硫酰胺；b)将步骤a)中的硫酰胺与肼反应以形成肼酰胺；c)将步骤b)中的肼酰胺与羰基化试剂或硫代羰基化试剂反应。在一个实施例中，本发明是一种合成公式(IA)的化合物的方法：或其互变异构体、药学上可接受的盐、溶剂合物、包合物或前药，包括将公式(IIA)的化合物与氧化剂反应，从而产生公式(IA)的化合物。本发明还涉及一种制备由以下结构式表示的化合物或其互变异构体的方法：或其互变异构体、药学上可接受的盐、溶剂合物、包合物或前药。该方法包括在汞盐的存在下，将由以下结构式表示的第一起始化合物与由以下结构式表示的第二起始化合物反应。
• TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY
  申请人：Ying Weiwen

  公开号：US20100093717A1

  公开（公告）日：2010-04-15

  The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of treating or inhibiting angiogenesis in a subject in need thereof and methods for blocking, occluding, or otherwise disrupting blood flow in neo vasculature, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

  本发明涉及取代的三唑化合物和包含取代的三唑化合物的组合物。本发明还涉及治疗或抑制需要的受体中的血管生成的方法，以及用于阻塞、闭塞或以其他方式破坏新生血管中的血流的方法，包括向受体中给予本发明的取代三唑化合物或包含这种化合物的组合物。
• Method for treating non-hodgkin's lymphoma
  申请人：Foley Kevin

  公开号：US20080004276A1

  公开（公告）日：2008-01-03

  The present invention relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating non-Hodgkin's lymphoma, in a subject in need thereof.

  本发明涉及抑制Hsp90在需要的受体中的活性的方法，以及用于治疗需要的非霍奇金淋巴瘤的方法。